T3 Pharmaceuticals AG’s CHF19.3 Million Series C Financing Round

VISCHER advises T3 Pharmaceuticals AG on all legal issues related to the transaction.

T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, closed its third financing round, raising over 25M CHF.

The financing was co-led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital SA, Wille Finance AG and private investors, who all participated in the round.

This latest financing brings T3 Pharma’s total funding since the launch of the Company in 2015 to 40 million CHF.

T3 Pharma will use the funds primarily to progress its lead candidate, T3P-Y058-739, through clinical studies. The Phase 1/2 clinical study in solid tumors is planned to start in early 2021.

The VISCHER team includes Christian Wyss (Partner, Corporate / M&A, in picture), Pauline Pfirter (Associate, Corporate / M&A), Ruben Masar (Associate, Corporate / M&A), and Gian Geel (Associate, Employment).

Involved fees earner: Gian Geel – VISCHER AG; Ruben Masar – VISCHER AG; Pauline Pfirter – VISCHER AG; Christian Wyss – VISCHER AG;

Law Firms: VISCHER AG;

Clients: T3 Pharmaceuticals AG;